These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29333576)

  • 1. Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse.
    Delgado Bolton RC; Giammarile F
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):822-823. PubMed ID: 29333576
    [No Abstract]   [Full Text] [Related]  

  • 2. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
    Ahmadzadehfar H; Essler M; Rahbar K; Afshar-Oromieh A
    PET Clin; 2018 Oct; 13(4):491-503. PubMed ID: 30219184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioisotope Therapy of Bone Metastases-A Nuclear Medicine Perspective.
    Leung E
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S34-S35. PubMed ID: 31501063
    [No Abstract]   [Full Text] [Related]  

  • 4. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
    Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of bone metastases with radium-223. German guidelines].
    Pöppel TD; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Scheidhauer K; Schenck M; Sonnenschein W; Gabriel M
    Nuklearmedizin; 2016 Sep; 55(5):177-86. PubMed ID: 27417067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted radionuclide therapy for castration-resistant prostate cancer].
    Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
    Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
    Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Radium-223 for the treatment of bone metastasis of prostate cancer].
    Xu XF; Wei ZF; Zhang ZY
    Zhonghua Nan Ke Xue; 2017 Jan; 23(1):78-81. PubMed ID: 29658243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
    Rubini G; Nicoletti A; Rubini D; Asabella AN
    Cancer Biother Radiopharm; 2014 Feb; 29(1):1-11. PubMed ID: 24180669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
    Mortensen J; Højgaard L
    Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nuclear medicine in oncotherapy].
    Pávics L; Besenyi Z
    Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in nuclear medicine in the management of bone metastases: a review and perspective.
    Damerla V; Packianathan S; Boerner PS; Jani AB; Vijayakumar S; Vijayakumar V
    Am J Clin Oncol; 2005 Oct; 28(5):513-20. PubMed ID: 16199993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radium-223 dichloride for the treatment of metastatic prostate cancer.
    Turner PG; O'Sullivan J
    Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
    Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
    Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radium-223 for the treatment of prostate cancer.
    Hafeez S; Parker C
    Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment.
    Bombardieri E; Evangelista L; Ceresoli GL; Boccardo F
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):5-7. PubMed ID: 26381776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.